Bobby Chawla, DO
Hematology & Oncology · Caldwell, IDNPI 1598956963
Payments from drug & device makers
Across 1,426 payments — averaging $758.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$327K
- AstraZeneca$211K
- Incyte Corporation$172K
- GSK$63K
- Takeda Pharmaceuticals U.S.A., Inc.$61K
- Amgen$42K
- plus $205K from 54 others
What the payments were for
- Consulting fees$84,1618%
- Speaking & faculty fees$790,17376%
- Travel & lodging$127,93012%
- Food & beverage$31,1613%
- Education$1,0810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,081,009 in reported general payments places this provider in the 95th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 107 | $1,547,397 |
| ImbruvicaIbrutinib | 84 | $1,317,823 |
| Lenalidomide | 47 | $701,031 |
| JakafiRuxolitinib Phosphate | 41 | $687,784 |
| RevlimidLenalidomide | 32 | $576,450 |
| IbrancePalbociclib | 37 | $567,028 |
| InlytaAxitinib | 22 | $415,482 |
| RydaptMidostaurin | 12 | $405,813 |
| JaypircaPirtobrutinib | 12 | $269,890 |
| TagrissoOsimertinib Mesylate | 13 | $218,852 |
| XtandiEnzalutamide | 15 | $214,033 |
| Abiraterone Acetate | 72 | $191,360 |
| Everolimus | 30 | $117,803 |
| EliquisApixaban | 101 | $80,525 |
| Imatinib Mesylate | 26 | $45,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $211,123 | $1,766,249120 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $361 | $1,317,82384 claims |
| PfizerIbrance, Inlyta, Eliquis | $434 | $1,063,034160 claims |
| Incyte CorporationJakafi | $172,451 | $687,78441 claims |
| Bristol Myers SquibbRevlimid | $8,025 | $576,45032 claims |
| NovartisRydapt | $1,205 | $405,81312 claims |
| Lilly USA, LLCJaypirca, Olanzapine | $87 | $270,86386 claims |
| Astellas Pharma US IncXtandi | $353 | $214,03315 claims |
| AbbVieCreon | $2,509 | $8,90920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 34 hematology & oncology providers in Idaho.
Other hematology & oncology in Caldwell
- Danko MartincicPost Falls$3.5M
- Kerry PulverBoise$778K
- Dan ZuckermanBoise$537K
- William KreisleBoise$296K
- Christian ShullIdaho Falls$150K
- Ian QureshiNampa$49K
- Shane AhlersBoise$46K
- Olga DermanBoise$29K
- Paul WhiteCoeur D Alene$26K
- Andrew PiersonBoise$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.